U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

             QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                  For the quarterly period ended March 31, 2007

                        Commission File Number: 000-17064

                           IMPLANT TECHNOLOGIES, Inc.

        (Exact name of small business issuer as specified in its charter)


         Minnesota                                         41-1430130
----------------------------                   ---------------------------------
(State of other jurisdiction of                (IRS Employer Identification No.)
 incorporation or organization)


             5353 Manhattan Circle Suite 101 Boulder, Colorado 80303
             -------------------------------------------------------
          (Address of principal executive offices including zip code)

                                 (303) 499-6000
                                 --------------
                           (Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the preceding 12 months (or for such
shorter period that the Registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.

                                   Yes X  No___

Indicate by checkmark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act)

                                   Yes X  No___

As of March 31, 2007, the Registrant had 99,408,464 shares of common stock, $.01
par value per share, outstanding.

Transitional Small Business Disclosure Format (check one): Yes__ No X


<PAGE>


                                      INDEX
                                      -----
                                                                           Page
                                                                          Number
                                                                          ------
Part I.   Financial Information

 Item I.   Financial Statements

           Balance Sheets as of March 31, 2007
            (unaudited) and June 30, 2006                                   2

           Statements of Operations, Three Months
            ended March 31, 2007 and 2006 (unaudited)                       3

           Statements of Operations, Nine Months
            ended March 31, 2007 and 2006 (unaudited)                       4

           Statements of Cash Flows, Nine Months
            ended March 31, 2007 and 2006 (unaudited)                       5

           Notes to Financial Statements                                    6

 Item 2.   Management's Discussion and Analysis of
            Financial Conditions and Results of
            Operations                                                      8

Part II.  Other Information                                                 9



<PAGE>



                            IMPLANT TECHNOLGIES, INC.
                          (A Development Stage Company)
                                 BALANCE SHEETS

                                     ASSETS

                                                  March 31,       June 30,
                                                    2007            2006
                                                 (Unaudited)    (See Note 1)
                                                 -----------    -----------
Current Assets
  Cash                                                   658           --
                                                 -----------    -----------
  Total Current Assets                                   658           --
                                                 -----------    -----------
Total Assets                                     $       658    $      --
                                                 ===========    ===========


LIABILITIES AND STOCKHOLDERS' (DEFICIT)

Current Liabilities:
  Accounts Payable                               $     8,012    $      --
                                                 -----------    -----------
  Total Current Liabilities                            8,012           --
                                                 -----------    -----------

Total Liabilities                                      8,012           --
                                                 -----------    -----------

Stockholders' (Deficit):
Common Stock, $.01 par value,
    800,000,000 shares authorized
    99,408,464 and 19,408,464
    shares issued and outstanding
    respectively                                     994,085        194,085
Additional paid-in capital                         2,560,103      3,340,103
Accumulated (deficit)                             (3,534,188)    (3,534,188)
Subscriptions Receivable                              (7,000)          --
Accumulated (deficit) during development stage       (20,354)          --
                                                 -----------    -----------
Total Stockholders' (Deficit)                         (7,354)          --
                                                 -----------    -----------

Total Liabilities and Stockholders' (Deficit)    $       658    $      --
                                                 ===========    ===========





The accompanying notes are an integral part of the financial statements.

                                        2
<PAGE>



                           IMPLANT TECHNOLOGIES, INC.
                          (A Development Stage Company)
                            STATEMENTS OF OPERATIONS
                                   (Unaudited)



                                                     Three Months Ended
                                                  March 31,       March 31,
                                                    2007            2006
                                                ------------    ------------

Revenues                                        $       --      $       --
                                                ------------    ------------
Expenses:
  Audit Fees                                           1,700            --
  Attorney Fees                                          560            --
  Bank Charges                                             9            --
  Transfer Agent Fees                                    908            --
  Edgar Filing Fees                                      290            --
                                                ------------    ------------
Net (Loss)                                      $     (3,467)           --
                                                ------------    ------------

Per Share                                       $        nil    $        nil
                                                ============    ============

Weighted Average Number of Shares Outstanding     99,408,464      19,408,464
                                                ============    ============












The accompanying notes are an integral part of the financial statements.


                                        3
<PAGE>


                           IMPLANT TECHNOLOGIES, INC.
                          (A Development Stage Company)
                            STATEMENTS OF OPERATIONS
                                   (Unaudited)


                                                                      For the
                                                                   Period from
                                                                     April 26,
                                                                  2006 (date of
                                                                  reinstatement)
                                          Nine Months Ended          through
                                      March 31,       March 31,      March 31,
                                        2007            2006           2007
                                    ------------    -----------   -------------

Revenues                            $       --      $      --     $        --
                                    ------------    -----------   -------------
Expenses:
  Audit Fees                              11,700           --            11,700
  Attorney Fees                            3,264           --             3,264
  Bank Charges                                54           --                54
  Transfer Agent Fees                      2,753           --             2,753
  Edgar Filing Fees                          612           --               612
  Mailing Fees                             1,931           --             1,931
  General Corporate Fees                      40           --                40
                                    ------------    -----------   -------------
Net (Loss)                          $    (20,354)         (--)          (20,354)
                                    ------------    -----------   -------------

Per Share                           $        nil    $       nil   $         nil
                                    ============    ===========   =============
Weighted Average Number of Shares
 Outstanding                          53,554,421     19,408,464      46,929,086
                                    ============    ===========   =============










The accompanying notes are an integral part of the financial statements.

                                        4
<PAGE>
<TABLE>
<CAPTION>

                           IMPLANT TECHNOLOGIES, INC.
                          (A Development Stage Company)
                            STATEMENTS OF CASH FLOWS
                                   (Unaudited)
                                                                               For the
                                                                            Period from
                                                                              April 26,
                                                                           2006 (date of
                                                                           reinstatement)
                                                   Nine Months Ended          through
                                               March 31,       March 31,      March 31,
                                                 2007            2006           2007
                                             ------------    -----------   -------------
<S>                                          <C>             <C>           <C>
Cash Flows from Operating Activities:
  Net (loss)                                 $    (20,354)   $      --     $     (20,354)
Adjustments to reconcile net loss
 To net cash used in operating activities:
  Increase in Accounts Payable                      8,012           --             8,012
                                             ------------    -----------   -------------
Net Cash (Used in) Operating
 Activities                                       (12,342)          --           (12,342)
                                             ------------    -----------   -------------

Cash Flows from Investing
 Activities                                          --             --              --
                                             ------------    -----------   -------------

Cash Flows from Financing
 Activities
Issuance of Common stock                           20,000           --            20,000
  Subscriptions Receivable                         (7,000)          --            (7,000)
                                             ------------    -----------   -------------
Net Cash Provided by Financing
 Activities                                        13,000           --            13,000
                                             ------------    -----------   -------------

Increase (Decrease) in Cash                           658           --               658

Cash, Beginning of Period                            --             --              --
                                             ------------    -----------   -------------
Cash, End of Period                          $        658    $      --     $         658
                                             ============    ===========   =============
Interest Paid                                $       --      $      --     $        --
                                             ============    ===========   =============
Income Taxes Paid                            $       --      $      --     $        --
                                             ============    ===========   =============
</TABLE>





The accompanying notes are an integral part of the financial statements.

                                        5
<PAGE>


                           IMPLANT TECHNOLOGIES, INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                           March 31, 2007 (Unaudited)


(1) Unaudited Financial Statements

The balance sheet as of March 31, 2007, the statements of operations and the
statements of cash flows for the three month and nine month periods ended March
31, 2007 and 2006, have been prepared by Implant Technologies, Inc. (Company)
without audit, pursuant to the rules and regulations of the Securities and
Exchange Commission. Certain information and footnote disclosures, normally
included in the financial statements prepared in accordance with accounting
principles generally accepted in the United States of America, have been
condensed or omitted as allowed by such rules and regulations, and the Company
believes that the disclosures are adequate to make the information presented not
misleading. In the opinion of management, all adjustments (which include only
normal recurring adjustments) necessary to present fairly the financial
position, results of operations and changes in financial position at March 31,
2007 and for all periods presented, have been made.

It is suggested that these statements be read in conjunction with the June 30,
2006 audited financial statements and the accompanying notes included in the
Company's Registration on Form 10SB12G, filed with the Securities and Exchange
Commission.

(2) Basis of Presentation

The accompanying financial statements have been prepared in conformity with
generally accepted accounting principles in the United States of America, which
contemplates continuation of the Company as a going concern. However, the
Company has negative working capital and stockholders' deficits and no active
business operations, which raises substantial doubt about its ability to
continue as a going concern.

In view of these matters, realization of certain of the assets in the
accompanying balance sheet is dependent upon continued operations of the
Company, which in turn is dependent upon the Company's ability to meet its
financial requirements, raise additional capital, and the success of its future
operations. However, the Company has sustained losses from operations and has
net capital and working capital deficits, which raises substantial doubt about
its ability to continue as a going concern.

Management has opted to resume the filing of Securities and Exchange Commission
(SEC) reporting documentation and then to seek a business combination.
Management believes that this plan provides an opportunity for the Company to
continue as a going concern.

(3) Development Stage Company

Based upon the Company's business plan, it is a development stage enterprise
since planned principal operations have not yet commenced. Accordingly, the
Company presents its financial statements in conformity with the accounting
principles generally accepted in the United States of America that apply in
establishing operating enterprises. As a development stage enterprise, the
Company discloses the deficit accumulated during the development stage and the
cumulative statements of operations and cash flows from commencement of
development stage to the current balance sheet date. The development stage began
in April 2006 when the Company was reinstated as a Minnesota corporation.



                                        6
<PAGE>


                           IMPLANT TECHNOLOGIES, INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                           March 31, 2007 (Unaudited)


(4) Common Stock

Pursuant to the Articles of Incorporation as amended, the Company is authorized
to issue 800,000,000 common shares with a par value of $.01.

During October 1982, the Company completed a public offering pursuant to a
registration on Form S-18 under the Securities Act of 1933, in the offering to
the public of 2,000,000 shares at $0.25 per share totaling $500,000. Net
proceeds to the Company after deducting costs of the offering of $50,000,
amounted to $450,000. Between December 1982 and April 1991 the Company issued
common stock to pay for services and debts of the Company.

On December 4, 2006, the Company issued 80,000,000 shares of its common stock to
two individuals, (Sanford Schwartz and Michael Friess), for $10,000 cash payment
and a $10,000 note payable to the Company. This transaction resulted in a change
in control of the Company. During January 2007, the Company collected $3,000 on
this note.












                                        7
<PAGE>


ITEM 2

                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                       CONDITION AND RESULTS OF OPERATIONS

Implant Technologies, Inc., the "Company" was incorporated under the laws of the
state of Minnesota in 1980. The Company was formed for the purpose of developing
and marketing medical products.

The Company generated no revenues during the quarter ended March 31, 2007, and
management does not anticipate any revenues until following the conclusion of a
merger or acquisition, if any, as contemplated by the Company's business plan.

The Company has limited capital. The Company anticipates operational costs will
be limited until such time as significant evaluation work is undertaken
regarding prospective mergers or acquisitions.

At March 31, 2007, the Company had no material commitments for capital
expenditures.

ITEM 3 CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures.

Our Chief Executive Officer and Chief Financial Officer (collectively the
"Certifying Officers") maintain a system of disclosure controls and procedures
that is designed to provide reasonable assurance that information, which is
required to be disclosed, is accumulated and communicated to management timely.
Under the supervision and with the participation of management, the Certifying
Officers evaluated the effectiveness of the design and operation of our
disclosure controls and procedures (as defined in Rule [13a-14(c)/15d-14(c)]
under the Exchange Act) within 90 days prior to the filing date of this report.
Based upon that evaluation, the Certifying Officers concluded that our
disclosure controls and procedures are effective in timely alerting them to
material information relative to our company required to be disclosed in our
periodic filings with the SEC.

(b) Changes in internal controls.

Our Certifying Officer has indicated that there were no significant changes in
our internal controls or other factors that could significantly affect such
controls subsequent to the date of his evaluation, and there were no such
control actions with regard to significant deficiencies and material weaknesses.


                                        8
<PAGE>


                           PART II. OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 2. Changes in Securities

In December 2006, the Company issued 80,000,000 shares of its common stock to
two individuals, for $10,000 cash payment and a $10,000 note payable to the
Company.

Item 3. Defaults upon Senior Securities

None.

Item 4. Submission of Matters to a Vote of Security Holders

On November 17, 2006 an annual meeting of shareholders was held where
shareholders approved the increase in authorized shares from 20 million shares
to 800 million shares, the adoption of Amended and Restated Articles of
Incorporation and the election of three nominated Directors.

Item 5. Other Information

None.

Item 6. Exhibits and Reports on Form 8-K

    (a) Exhibits:
        31(1) Certification of Chief Executive Officer Pursuant to
              Rule 13a-14(a) or Rule 15d-14(a).

        31(2) Certification of Chief Financial Officer Pursuant to
              Rule 13a-14(a) or Rule 15d-14(a).

        32(1) Certification of Chief Executive Officer Pursuant to Rule
              13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350, as
              Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
              2002.

        32(2) Certification of Chief Financial Officer Pursuant to Rule
              13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350, as
              Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
              2002.

    (b) Reports on Form 8-K:
        NONE




                                        9
<PAGE>



                                   SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this quarterly report to be signed
on its behalf by the undersigned, thereunto duly authorized.



REGISTRANT                            Implant Technologies, Inc.




BY(Signature)                         /s/ Michael Friess
(Name and Title)                      Michael Friess, President, Chief
                                      Executive Officer
(Date)                                April 26, 2007

BY(Signature)                         /s/ John Venette
(Name and Title)                      John Venette, Treasurer,
                                      Secretary and Chief Financial Officer
(Date)                                April 26, 2007









                                       10